CION Ameerpet
Types of Immunotherapy Explained · Biosimilars
Biosimilars — Are They the Same as the Original Product?
A biosimilar is a highly similar version of an approved biological medicine, made by a different manufacturer once the original loses patent protection. It is not a copy in the way a generic tablet is a copy, and it is not a different treatment. In India it reaches the market only through CDSCO's Similar Biologics pathway, which is built entirely around comparison with the reference product.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed August 2026
- Highly similar, not identical — No biological medicine is chemically identical between batches — including the original manufacturer's own.
- Approved by comparison, not assumption — CDSCO requires comparative analytical, non-clinical and clinical data before a biosimilar can be sold.
- The class and the target do not change — A PD-1, PD-L1 or CTLA-4 blocker releases the same brake on the immune system either way.
- Why families ask — Biosimilar entry is the biggest single cost lever in Indian immunotherapy — worth understanding properly, not from a sales pitch.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Start here
What is a biosimilar?
A biosimilar is a version of an already-approved biological medicine, made by another manufacturer after the original loses patent protection. Biological medicines are grown in living cells, so exact chemical copying is impossible. A biosimilar is therefore built to be highly similar to its reference product — matched on structure, target and behaviour, within limits regulators set in advance.
Almost all immunotherapy given as a day-care infusion in India belongs to one family: monoclonal antibodies. Checkpoint inhibitors are the best known of them. They work by blocking a brake on the immune system — the PD-1 receptor, its PD-L1 partner, or the separate CTLA-4 brake. Every one of those is a biological medicine. So any lower-cost version of one is a biosimilar. It is never a generic.
The phrase highly similar unsettles people, so it is worth explaining rather than glossing over. Living cells do not produce identical output twice. The reference product itself varies slightly between batches — the original made last year is not chemically identical to the one made this year. Regulators fix in advance how much variation is acceptable, then require every batch, original or biosimilar, to fall inside it.
Did you know?
The word similar is doing precise regulatory work here. It means the differences that remain have been measured and shown to have no clinically meaningful effect — not that nobody has looked.
The distinction that matters
Is a biosimilar the same as a generic?
No. A generic is an identical chemical copy of a small-molecule tablet. A biosimilar is a highly similar version of a large molecule grown in living cells, and it needs its own comparative evidence package to be approved. The two words are not interchangeable, and in India they travel through different regulatory routes.
This matters most at the point where someone is trying to sell you something. If a product is offered as a generic immunotherapy, the description itself is wrong for this class of medicine — which is reason enough to stop and ask for its CDSCO marketing approval before anything is bought or infused.
| Reference biological medicine | Biosimilar | Generic | |
|---|---|---|---|
| What it is | The first approved version of the molecule | A highly similar version of the same biological medicine | An identical chemical copy of a small-molecule drug |
| How it is made | Grown in living cells | Grown in living cells | Chemical synthesis |
| Size and complexity | Large, folded protein | Large, folded protein | Small, simple molecule |
| Indian approval route | Full clinical data package | Similar Biologics pathway — comparative analytical, non-clinical and clinical data | Bioequivalence data |
| Chemically identical to the original? | Not even to its own earlier batches | Highly similar, not identical | Yes |
| Applies to checkpoint inhibitors? | Yes | Yes | No — they are biological medicines |
If you remember one row from this table, make it the last one.
The approval standard, stated plainly
Is a biosimilar as effective as the original?
CDSCO does not approve a biosimilar unless comparative data show no clinically meaningful difference from the reference product in quality, safety, efficacy and immunogenicity. That is the standard approval is granted against. It is a regulatory judgement made product by product — not a comparison this page is making between any two products you may be offered.
The distinction is where marketing usually takes over. Nobody can tell you from a webpage that one specific product will behave in your body the way another would. What can honestly be said is what the regulator required before allowing it to be sold at all — and that requirement is comparative at every stage.
There is one part of this that patients are rarely told, and it deserves saying. A biosimilar is sometimes approved for several of the reference product's indications on the strength of a comparative study conducted in just one of them. Regulators call this extrapolation, and it is a deliberate, reasoned decision rather than an oversight — it rests on the argument that if the molecule is shown to behave the same way, the disease setting should not change that. It is still a reasonable thing for a family to ask about.
What this page is not saying. It is not saying a biosimilar will work for you, or that any product should be preferred over another. Whether immunotherapy is appropriate at all, and which product is used, are clinical decisions taken by your treating oncologist with the tumour board — after your biomarker results, cancer type and fitness for treatment have been reviewed.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Ask What Is Being Given, Before It Is Given
A 45-minute consultation to go through the plan line by line — the class, the product, the schedule and the indicative cost, in writing.
The Indian pathway
How is a biosimilar approved in India?
Through the CDSCO and Department of Biotechnology Guidelines on Similar Biologics, which follow WHO guidance on similar biotherapeutic products. The manufacturer proves comparability in stages — laboratory first, then non-clinical, then a comparative clinical study, with immunogenicity testing throughout. Safety reporting continues after the product reaches the market.
The order is the logic of the whole pathway. A biosimilar developer is not asked to rediscover that the mechanism works — the original trial programme settled that. They are asked to show, with progressively more sensitive tests, that their molecule cannot be told apart from the reference product in ways that would matter to a patient.
- 1
Choose and characterise the reference product
A single approved reference product is fixed at the start. Every comparison from that point on is made against it.
- 2
Analytical comparability
Structure, folding, purity, sugar attachments and target binding, measured side by side in the laboratory. This stage carries most of the evidential weight.
- 3
Non-clinical comparison
Cell-based and, where required, animal studies confirm the biological activity matches before any patient is involved.
- 4
Comparative clinical study
Usually smaller than the original programme, because the question has changed: it is designed to detect a difference, not to establish benefit from scratch.
- 5
Immunogenicity testing and post-marketing safety
Whether the body forms antibodies against the medicine is tested specifically, and adverse-event reporting continues after approval under a risk management plan.
Approval is granted to a specific product from a specific manufacturing site — not to a company, and not to the molecule as a category. That is why the practical question is always about the exact product on the carton.
In the infusion chair
What changes for you, and what does not?
Very little changes in how treatment is actually given. The target, the mechanism, the route, the approved dose and the monitoring schedule stay the same, because they belong to the treatment class rather than to the manufacturer. What changes is the name printed on the carton and, in most cases, the price.
| Part of your treatment | Changes with a biosimilar? | What that means in practice |
|---|---|---|
| The target and the mechanism | No | A PD-1, PD-L1 or CTLA-4 blocker still releases the same brake on the immune system |
| Route and setting | No | Still an intravenous infusion, given as day care at CION centres |
| Approved dose and interval | No | An approved biosimilar carries the reference product's approved dosing |
| Monitoring blood tests | No | Thyroid, liver, kidney and blood-count checks are driven by the class, not the brand |
| Response-assessment imaging | No | Scans are timed to your treatment plan and coordinated at partner imaging centres |
| Immune-related side effects | No | The same reactions are watched for, and managed the same way if they occur |
| Name and manufacturer on the carton | Yes | Worth reading, recording in your file, and checking against CDSCO approval |
| Price | Usually yes | Biosimilar entry lowers the drug line; indicative, as of August 2026 |
Two related pages go deeper on the class itself: how PD-1 and PD-L1 inhibitors differ, and why CTLA-4 inhibitors are usually combined with another agent.
Did you know?
Biosimilar entry is the single largest cost lever in Indian immunotherapy — but it moves only the drug line. Day-care charges, monitoring blood tests and response-assessment scans are billed the same either way. Indicative, as of August 2026.
Before the first cycle
What should you ask about the product being used?
Three questions cover it. Which exact product is being used and who makes it, does that product hold current CDSCO approval for your indication, and is it the reference product or a biosimilar. All three are ordinary questions. Ask that the answers go into your file, not just into a conversation.
- Which exact product is being used, and who manufactures it? The name on the carton, not just the class. This one question closes off most of what can go wrong.
- Does it hold current CDSCO marketing approval for my indication? Approval is specific to a product and to an indication, so the answer should be specific too.
- Is this the reference product or a biosimilar? Either answer is a legitimate one. You are entitled to know which you are receiving, and to have the batch number and expiry recorded in your file.
Funding the treatment from abroad? Ask for the itemised estimate in Indian rupees, dated, and ask specifically what is excluded — imaging, admissions and the management of side effects usually are. A lower drug price does not change how many cycles are given; that is decided on response and tolerance.
No rushed decisions
Understand It First, Then Decide
Every plan goes to a tumour board, and every question about the medicine gets a plain answer — including the option of not starting.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Biosimilars: Your Questions Answered
What is a biosimilar, in plain terms?
A biosimilar is a version of an already-approved biological medicine, made by a different manufacturer once the original product's patent protection has ended. Biological medicines are large molecules grown inside living cells, so no two production runs are ever chemically identical — that is true of the original manufacturer's own batches too. A biosimilar is therefore called highly similar rather than identical. It is developed against the reference product deliberately, to match its structure, its target and its behaviour in the body within limits regulators set in advance.
Is a biosimilar the same as a generic medicine?
No, and the difference is not a technicality. A generic is an identical chemical copy of a small-molecule tablet, approved largely on evidence that the body absorbs it the same way. Biological medicines cannot be copied that way, because they are grown in living cells rather than synthesised. India recognises this with a separate route: the CDSCO and Department of Biotechnology Guidelines on Similar Biologics. So a generic checkpoint inhibitor is not a category that exists. If a product is described to you in those words, ask for its approval status before anything else.
Is a biosimilar as effective as the original product?
This is a regulatory judgement made product by product, not a marketing claim. CDSCO does not grant approval unless comparative data show no clinically meaningful difference from the reference product in quality, safety, efficacy and immunogenicity. That standard is what approval means, and it is the honest answer to the question. It is not a comparison between two specific products that CION is making on your behalf. Which medicine is appropriate for you stays a clinical decision for your treating oncologist and the tumour board.
How is a biosimilar approved in India?
Approval follows the CDSCO and Department of Biotechnology Guidelines on Similar Biologics, which are aligned with WHO guidance on similar biotherapeutic products. The manufacturer must first show extensive analytical comparability with the reference product — structure, purity and target binding. Non-clinical comparison follows. Only then is a comparative clinical study run, usually smaller than the original trial programme, because its purpose is to detect a difference rather than to establish benefit from scratch. Immunogenicity testing is required, and safety reporting continues after marketing.
Will my dose, schedule or monitoring change if a biosimilar is used?
Generally no. An approved biosimilar carries the same route, the same strength options and the same approved dosing as its reference product, and it is given the same way — for checkpoint inhibitors, as a day-care infusion. Your monitoring blood tests and response-assessment scans are driven by the treatment class and your own clinical picture, not by which manufacturer made the vial. What changes is the name on the carton and, usually, the price. Any switch part-way through treatment should be a documented decision made by your oncologist.
Can I ask which product is being used and where it came from?
Yes, and you should. You are entitled to know the product name on the carton, its manufacturer, and that it holds current CDSCO marketing approval for the indication you are being treated for. Ask that the batch number and expiry are recorded in your file, and that the product came through the hospital pharmacy or its authorised distributor. Biological medicines are cold-chain products, stored between 2°C and 8°C and never frozen. None of these are awkward questions, and a good team answers them without being asked twice.